+

WO1999022763A3 - Encapsulated immunomodulators useful as vaccine adjuvants - Google Patents

Encapsulated immunomodulators useful as vaccine adjuvants Download PDF

Info

Publication number
WO1999022763A3
WO1999022763A3 PCT/US1998/023313 US9823313W WO9922763A3 WO 1999022763 A3 WO1999022763 A3 WO 1999022763A3 US 9823313 W US9823313 W US 9823313W WO 9922763 A3 WO9922763 A3 WO 9922763A3
Authority
WO
WIPO (PCT)
Prior art keywords
encapsulated
immunomodulator
vaccine adjuvants
useful
adjuvant
Prior art date
Application number
PCT/US1998/023313
Other languages
French (fr)
Other versions
WO1999022763A2 (en
Inventor
Richard S Dondero
Bruce C Galton
Leslie S Casey
Original Assignee
Cistron Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cistron Biotechnology Inc filed Critical Cistron Biotechnology Inc
Priority to JP2000518694A priority Critical patent/JP2001521908A/en
Priority to AU12084/99A priority patent/AU1208499A/en
Priority to IL13548098A priority patent/IL135480A0/en
Priority to CA002307541A priority patent/CA2307541A1/en
Priority to EP98955231A priority patent/EP1027071A2/en
Publication of WO1999022763A2 publication Critical patent/WO1999022763A2/en
Publication of WO1999022763A3 publication Critical patent/WO1999022763A3/en
Priority to AU2003200723A priority patent/AU2003200723B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55533—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention concerns compositions comprising an encapsulated immunomodulator, such as cytokines and lymphokines, that is useful as an adjuvant for stimulating an immune response when administered to a human or animal. For example, a lymphokine such as IL-1α or IL-1β can be used as an immunomodulator encapsulated in a matrix according to the invention. The encapsulated composition can include a vaccine antigen, such as whole inactivated or attenuated virus, recombinant or synthetic peptides, and other antigenic materials. The encapsulation matrix can be natural or synthetic. The present invention also pertains to the use of an encapsulated immunomodulator in a human or animal as an adjuvant to increase immune responses to an antigen or other material to which an immune response is desired.
PCT/US1998/023313 1997-10-31 1998-11-02 Encapsulated immunomodulators useful as vaccine adjuvants WO1999022763A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2000518694A JP2001521908A (en) 1997-10-31 1998-11-02 Encapsulated immunomodulators useful as vaccine adjuvants
AU12084/99A AU1208499A (en) 1997-10-31 1998-11-02 Encapsulated immunomodulators useful as vaccine adjuvants
IL13548098A IL135480A0 (en) 1997-10-31 1998-11-02 Encapsulated immunomodulators useful as vaccine adjuvants
CA002307541A CA2307541A1 (en) 1997-10-31 1998-11-02 Encapsulated immunomodulators useful as vaccine adjuvants
EP98955231A EP1027071A2 (en) 1997-10-31 1998-11-02 Encapsulated immunomodulators useful as vaccine adjuvants
AU2003200723A AU2003200723B2 (en) 1997-10-31 2003-02-28 Encapsulated immunomodulators useful as vaccine adjuvants

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96240797A 1997-10-31 1997-10-31
US08/962,407 1997-10-31

Publications (2)

Publication Number Publication Date
WO1999022763A2 WO1999022763A2 (en) 1999-05-14
WO1999022763A3 true WO1999022763A3 (en) 1999-08-05

Family

ID=25505819

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/023313 WO1999022763A2 (en) 1997-10-31 1998-11-02 Encapsulated immunomodulators useful as vaccine adjuvants

Country Status (6)

Country Link
EP (1) EP1027071A2 (en)
JP (1) JP2001521908A (en)
AU (1) AU1208499A (en)
CA (1) CA2307541A1 (en)
IL (1) IL135480A0 (en)
WO (1) WO1999022763A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1737481A4 (en) * 2004-02-27 2008-04-02 Vaxconsulting Peptides of il1 beta and tnf alpha and method of treatment using same
US20090068254A1 (en) 2005-09-30 2009-03-12 Lipoxen Technologies Limited Multivalent liposomal vaccine compositions comprising polysaccharide antigens and a protein adjuvant
ES2664753T3 (en) 2007-12-07 2018-04-23 Glaxosmithkline Biologicals Sa Immune response induction compositions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03170498A (en) * 1989-11-29 1991-07-24 Teikoku Hormone Mfg Co Ltd Peptide and drug having interleukin-1 like activity and containing the peptide
WO1997049423A2 (en) * 1996-06-24 1997-12-31 Yissum Research Development Company Of The Hebrew University Of Jerusalem Liposomal influenza vaccine composition and method

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0604727A1 (en) * 1992-12-31 1994-07-06 American Cyanamid Company Improved immunogenicity of a vaccine by incorporation of a cytokine within an immune-stimulating complex containing an antigen

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03170498A (en) * 1989-11-29 1991-07-24 Teikoku Hormone Mfg Co Ltd Peptide and drug having interleukin-1 like activity and containing the peptide
WO1997049423A2 (en) * 1996-06-24 1997-12-31 Yissum Research Development Company Of The Hebrew University Of Jerusalem Liposomal influenza vaccine composition and method

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 9136, Derwent World Patents Index; Class B04, AN 91-262316, XP002104336 *
LIMOR C ET AL: "Characterization of PLGA microspheres for the controlled delivery of IL-1alpha for tumor immunotherapy", JOURNAL OF CONTROLLED RELEASE, vol. 43, no. 2-3, 18 January 1997 (1997-01-18), pages 261-272, XP004069894 *

Also Published As

Publication number Publication date
AU1208499A (en) 1999-05-24
EP1027071A2 (en) 2000-08-16
IL135480A0 (en) 2001-05-20
JP2001521908A (en) 2001-11-13
CA2307541A1 (en) 1999-05-14
WO1999022763A2 (en) 1999-05-14

Similar Documents

Publication Publication Date Title
WO2001039803A3 (en) Interleukin-1 muteins useful as vaccine adjuvants
ATE496630T1 (en) IMMUNOLOGICAL COMPOSITION AND VACCINES CONTAINING AN ADJUVANT CONSISTING OF N-FORMYL-METHIONYL PEPTIDES
FR2686896B1 (en) MUTANT ATTENUE OF LISTERIA MONOCYTOGENES; RECOMBINANT STRAIN OF LISTERIA MONOCYTOGENES, USE AS HETEROLOGOUS VECTORS OF VACCINE ANTIGENS AND USE AS VACCINE OR DIAGNOSTIC COMPOSITION.
ATE229978T1 (en) HELICOBACTER PROTEINS AND VACCINES
CA2143823A1 (en) Retro-, inverso - and retro-inverso synthetic peptide analogues
PT1090033E (en) HCV ENVELOPE PROTEIN PARTICLES: USED FOR VACCINATION
WO2001095919A3 (en) A recombinant non-replicating virus expressing gm-csf and uses thereof to enhance immune responses
ATE392904T1 (en) PHARMACEUTICAL COMPOSITION FOR IMMUNO-STIMULATION AND FOR PREPARATION OF VACCINES CONTAINING AN ANTIGEN AND, AS ADJUVANTS, AN IMMUNOGENIC OLIGODESOXYNUCLEOTIDE AND A POLYCATIONIC POLYPEPTIDE
NZ331651A (en) BSW17 peptide immunogens for vaccination against and treatment of allergy
AU7980794A (en) Methods and compositions for microencapsulation of antigens for use as vaccines
EP1611897A3 (en) Whole or disrupted insect cells as adjuvant for antigens
FI920132A0 (en) STABILA VACCINKOMPOSITIONER INNEHAOLLANDE INTERLEUKINER.
NZ309659A (en) Composition comprising LbeIF4A and/or LmeIF4A polypeptides (Leishmania antigen) and methods for enhancing immune responses
WO2003007869A3 (en) Immunogenic compositions containing antigens, gene vectors and adjuvants-loaded biodegradable microspheres
DE69919984D1 (en) INTERLEUKIN-12 AND HERPES SIMPLEX VIRUSANTIGEN-CONTAINING VACCINES
ATE287957T1 (en) PEPTIDES DERIVED FROM THE BINDING (G) PROTEIN OF THE RESPIRATORY SYNZYTIAL VIRUS
DE69836744D1 (en) GROUP A STREPTOKOKEN VACCINE
WO1999022763A3 (en) Encapsulated immunomodulators useful as vaccine adjuvants
EP0236977A3 (en) Bovine virus diarrhea and hog cholera vaccines
TW200504216A (en) Immunization of fish with plant-expressed recombinant proteins
WO2000006198A3 (en) Adjuvant comprising pulmonary surfactant
SE9604296D0 (en) New pharmaceutical formulation of polypeptides
HK1025220A1 (en) Novel saponin compositions and uses thereof
DE60131975D1 (en) APPLICATION OF THE HERPES SIMPLEX VIRUS GLYCOPROTEINS-D TO THE SUPPRESSION OF IMMUNE RESPONSES
ES2091159A1 (en) Vaccine against helminth infection comprising Sm-14 fatty acid binding protein of Schistosoma mansoni

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 135480

Country of ref document: IL

AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA IL JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA IL JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 1998955231

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2307541

Country of ref document: CA

Ref country code: CA

Ref document number: 2307541

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 518694

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 12084/99

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 1998955231

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1998955231

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载